November 4, 2015
VBL Therapeutics to Report Third Quarter 2015 Financial Results on November 12

TEL AVIV, Israel, Nov. 4, 2015 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, November 12, 2015 at 8:30 a.m. Eastern Time to report third quarter 2015 financial results.

Thursday, November 12th @ 8:30am Eastern Time





Conference ID:




Replays, available through November 26th:

Toll Free:




Conference ID:


About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics’ pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.

CONTACT: INVESTOR CONTACT:         Michael Rice, Founding Partner         LifeSci Advisors, LLC         646-597-6979